US, AstraZeneca strike deal for COVID-19 antibody treatment touted by Donald Trump

By: |
October 10, 2020 10:10 AM

The agreement, under the Trump administration's Operation Warp Speed, is for developing a monoclonal antibody cocktail that can prevent COVID-19, especially in high-risk population like those over 80 years old, the U.S. Department of Health and Human Services said.

A clinical trial of the vaccine in the U.S. has been on hold for more than a month.

The U.S. government has awarded $486 million to AstraZeneca Plc to develop and secure supplies of up to 100,000 doses of COVID-19 antibody treatment, a similar class of drug that was used in treating President Donald Trump.

The agreement, under the Trump administration’s Operation Warp Speed, is for developing a monoclonal antibody cocktail that can prevent COVID-19, especially in high-risk population like those over 80 years old, the U.S. Department of Health and Human Services said.

The treatment has come under the spotlight after Trump was treated with Regeneron Pharmaceuticals’ antibody drug last week.

The president has also released a video on Twitter touting its benefits.In a call earlier on Friday, a top U.S. health official said the government was expecting to provide more than 1 million free doses of antibody treatments to COVID-19 patients, similar to the one that was administered to Trump.

Regeneron and Eli Lilly have both applied to the U.S. Food and Drug Administration for emergency use authorizations of their antibody treatments. AstraZeneca said it was planning to supply up to 100,000 doses starting toward the end of 2020 and that the U.S. government could acquire up to an additional one million doses in 2021 under a separate agreement.

Regeneron signed a $450 million deal in July to sell Operation Warp Speed enough doses of its antibody treatment, REGN-COV2, to treat around 300,000 people. Eli Lilly said on Friday it had not signed an agreement with Operation Warp Speed.

AstraZeneca plans to evaluate the treatment, AZD7442, which is a cocktail of two monoclonal antibodies, in two studies. One trial will evaluate the safety and efficacy of the experimental treatment to prevent infection for up to 12 months in about 5,000 participants, while the second will evaluate post-exposure preventative and pre-emptive treatment in roughly 1,100 participants.

Get live Stock Prices from BSE, NSE, US Market and latest NAV, portfolio of Mutual Funds, calculate your tax by Income Tax Calculator, know market’s Top Gainers, Top Losers & Best Equity Funds. Like us on Facebook and follow us on Twitter.

Financial Express is now on Telegram. Click here to join our channel and stay updated with the latest Biz news and updates.

Next Stories
1Sanofi, Glaxo to Supply 200 million Covid vaccine doses to Covax
2COVID-19 patients could suffer cognitive deficits equal to brain ageing by 10 years, says study
3China reports 42 new confirmed COVID-19 cases